BridgeBio Pharma Total Long-Term Assets 2018-2024 | BBIO

BridgeBio Pharma total long-term assets for the quarter ending September 30, 2024 were $0.220B, a 227.3% increase year-over-year.

  • BridgeBio Pharma total long-term assets for 2023 were $0.069B, a 7.27% decline from 2022.
  • BridgeBio Pharma total long-term assets for 2022 were $0.074B, a 40.14% decline from 2021.
  • BridgeBio Pharma total long-term assets for 2021 were $0.124B, a 103.96% increase from 2020.

BridgeBio Pharma Total Long-Term Assets 2018-2024 | BBIO

  • BridgeBio Pharma total long-term assets for 2023 were $0.069B, a 7.27% decline from 2022.
  • BridgeBio Pharma total long-term assets for 2022 were $0.074B, a 40.14% decline from 2021.
  • BridgeBio Pharma total long-term assets for 2021 were $0.124B, a 103.96% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$24.9B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$2.8B
Supernus Pharmaceuticals (SUPN)$2.1B
Amphastar Pharmaceuticals (AMPH)$1.7B
Personalis (PSNL)$396M
Taysha Gene Therapies (TSHA)$314M
Assembly Biosciences (ASMB)$95M
Sol-Gel Technologies (SLGL)$25M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M